Sign In
Buy ONCY
$0.94
+0.0237 (+2.58%)
At Close: Jun 23, 2026
Here's Why Oncolytics Biotech Inc. (ONCY) is Poised for a Turnaround After Losing 19.6% in 4 Weeks
11:29am, Wednesday, 18'th Aug 2021
The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2021 Results - Earnings Call Transcript
01:35pm, Friday, 06'th Aug 2021
Oncolytics Biotech Inc. (ONCY) CEO Matt Coffey on Q2 2021 Results - Earnings Call Transcript
Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results
07:00am, Friday, 06'th Aug 2021
- Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy i
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 41st Annual Growth Conference
06:30am, Friday, 06'th Aug 2021
SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genui
Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights
07:00am, Thursday, 22'nd Jul 2021
Conference call and webcast to take place on Friday, August 6, 2021, at 8:00 a.m. ET SAN DIEGO and CALGARY, AB, July 22, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) toda
Oncolytics Biotech® to Present at the Ladenburg Thalmann Healthcare Conference
07:00am, Wednesday, 30'th Jun 2021
SAN DIEGO and CALGARY, AB, June 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Company will present a corporate overview at the Ladenburg Thalma
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer
01:57pm, Thursday, 20'th May 2021
Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer
Oncolytics Biotech (ONCY) Stock: Over 4% Increase Pre-Market Explanation
07:50am, Thursday, 20'th May 2021
The stock price of Oncolytics Biotech, Inc. (NASDAQ: ONCY) increased by over 4% pre-market. This is why it happened.
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept
Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference
07:00am, Thursday, 13'th May 2021
Fireside chat to take place on Wednesday, May 19 at 5:25 pm ET SAN DIEGO and CALGARY, AB, May 13, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the Com
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
07:00am, Monday, 10'th May 2021
SAN DIEGO and CALGARY, AB, May 10, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting of Shareholders held o
Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results
07:00am, Friday, 07'th May 2021
- AWARE-1 clinical data validate clinical development strategy by confirming pelareorep's anti-tumor mechanism of action known to be associated with improved patient outcomes and ability to synergize
Oncolytics Biotech® Announces Annual General Meeting
07:00am, Friday, 30'th Apr 2021
Management will also provide its annual corporate update after the conclusion of the meeting SAN DIEGO, Calif. and CALGARY, AB, April 30, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY)
Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting
07:00am, Thursday, 29'th Apr 2021
SAN DIEGO and CALGARY, AB, April 29, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma tr
Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study
07:02am, Monday, 12'th Apr 2021
- Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classifica
